is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Anal cancer is similar biologically to cervical cancer and it has been a longstanding question as to whether methods to prevent cervical cancer including screening for and treating high-grade squamous intraepithelial lesions (HSIL) might also be used to prevent anal cancer. Until recently there have been few data to but the ANCHOR study has now shown that treatment of anal HSIL lesions reduces the risk of progression to anal cancer. This symposium will include a description of the ANCHOR study, and explore a number of questions that now arise, including: who should be targeted for screening; inclusion of anal screening in standard of care guidelines for at-risk individuals; methods to triage those who might benefit most from treatment; and novel methods of treatment.
Update on epidemiology of anal cancer
Clifford G. (France)
Results of the ANCHOR Study-implications for screening and treatment
Palefsky J. (USA)
Can the results of ANCHOR be applied to populations at risk for anal cancer other than those living with HIV?
Stier B. (USA)
Should screening for and treating anal HSIL be included in standard of care guidelines? What additional information is needed?
Deshmukh A. (USA)
Methylation analysis of anal cancer and pre-cancerous lesions- implications for cancer risk stratification of anal HSIL
Steenbergen R. (Netherlands)
Novel treatments for anal HSIL
Einstein M. (USA)
Roundtable - What is the next set of questions for the field to focus on?
Palefsky J. (USA)